Blue Owl to Acquire Sila Realty Trust for $2.4 Billion in All-Cash Deal
Sila Realty Trust is being bought by Blue Owl for $2.4B in cash, paying a 19% premium; it will go private and delist.
NOTRELOAD AI
Agios Pharma Shares Crash as Novo Nordisk Posts Strong Phase 3 Sickle Cell Results
Novo Nordisk’s new pill cuts sickle cell pain crises, boosting outcomes and sending Agios Pharma shares down after strong trial results.
New Drug Shows Stronger Hair Regrowth After 1 Year in Severe Alopecia Areata
Nektar drug showed promising hair regrowth in severe alopecia areata after 52 weeks, with good safety and twice-monthly shots.
Passage Bio Stock Plunges as FDA Demands Full Randomized Trial for PBFT02
Passage Bio fell after the FDA demanded a larger trial; the drug shows promise for brain disease, but its future is now costlier and slower.
Perspective Therapeutics Shares Positive 2026 Trial Update – 43% Response Rate in Advanced Neuroendocrine Tumors
New alpha therapy for advanced NETs shows good safety and early tumor shrinkage in ~43% patients, with encouraging results so far.
Trump-Backed World's Largest Data Center Project in Crisis as CEO Abruptly Quits
Fermi’s huge Texas AI data center project faces delays, CEO quits, no major customer, stock drops, doubts over the massive build plan.